Global Liver Institute

News

GLOBAL LIVER INSTITUTE

News
7th Annual Global Fatty Liver Day is less than 3 months away!

7th Annual Global Fatty Liver Day is less than 3 months away!

Fatty liver disease is a widespread issue that often goes undetected until it’s too late. It impacts millions worldwide leading to missed opportunities for early intervention and prevention. Studies highlight a concerning gap in identifying patients within the healthcare system who may have fatty liver disease unknowingly. We cannot afford to overlook the silent nature of this and this is why we are advocating for immediate action.

read more
GLI Commends Repurposed Livmarli’s FDA Approval for Patients over 5 with PFIC

GLI Commends Repurposed Livmarli’s FDA Approval for Patients over 5 with PFIC

(Washington, D.C. March 14, 2024) –Global Liver Institute (GLI) celebrates a win for rare disease patients with the breaking news of the U.S. FDA’s approval for Mirum Pharmaceuticals’ Livmarli to treat cholestasis pruritus in patients 5 and older that have been diagnosed with progressive familial intrahepatic cholestasis (PFIC), a rare, genetic disorder in which bile builds up in the liver.

read more
FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population

FDA’s Approval of Breakthrough NASH Treatment Opens Door for a Long-Neglected Patient Population

Today, Global Liver Institute (GLI) recognizes the importance of the first approval by the U.S. Food and Drug Administration (FDA) of a medication for nonalcoholic steatosis (NASH). Developed by Madrigal Pharmaceuticals, Rezdiffra™ (resmetirom) was approved for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis, in conjunction with diet and exercise.

read more
What’s next in line for fatty liver disease? – NASH News

What’s next in line for fatty liver disease? – NASH News

Madrigal Pharmaceuticals celebrates EMA’s validation of the Marketing Authorization Application for Resmetirom, a potential breakthrough therapy for NASH/MASH with liver fibrosis, while eagerly awaiting FDA’s decision, marking significant progress in the fight against liver-related mortality in Europe.

read more
What’s next in line for fatty liver disease? – NASH News

What’s next in line for fatty liver disease? – NASH News

Madrigal Pharmaceuticals celebrates EMA’s validation of the Marketing Authorization Application for Resmetirom, a potential breakthrough therapy for NASH/MASH with liver fibrosis, while eagerly awaiting FDA’s decision, marking significant progress in the fight against liver-related mortality in Europe.

read more
Navigating Liver Cancer Care – Liver Cancers News

Navigating Liver Cancer Care – Liver Cancers News

Please join us on April 18 for a liver cancer care webinar open to patients, caregivers, and health care professionals. Experts will discuss topics relevant to the care and treatment of liver cancer and its symptoms so that patients and providers alike can make informed care decisions.

read more
Navigating the Niche Nutritional Challenges of Rare Liver Diseases

Navigating the Niche Nutritional Challenges of Rare Liver Diseases

The lifestyle changes that come with a rare liver disease or any chronic condition can be daunting and frustrating. With a diet change, your meals, grocery bills, and even restaurant menus start to look different, not to mention the lists and diet recommendations from doctors that can be long and overwhelming.

read more
Six Tips to Help Your Patients through Organ Transplantation

Six Tips to Help Your Patients through Organ Transplantation

Dr. Alin Gragossian is a physician trained in both emergency medicine and critical care medicine at Equum Medical. Beyond her clinical roles, she serves as an associate medical director at Donor Network West, a nonprofit, organ procurement and tissue recovery organization serving Nevada and California. Notably, Dr. Gragossian brings a unique perspective to her work, having undergone a heart transplant in 2019 at the age of 30.

read more
Congress passes Continuing Resolution to extend federal funding into March 2024

Congress passes Continuing Resolution to extend federal funding into March 2024

Congress has again averted a government shutdown through the passage of a Continuing Resolution (CR) for funding the government into early March 2024. Election year politics make bipartisanship essential to advancing key legislation in the House and Senate. The current administration will be looking to finalize program regulations and advance key administration priorities before the elections.

read more